Cannabis Use Disorder Treatment Market
Market Insights on Cannabis Use Disorder Treatment covering sales outlook, demand forecast & up-to-date key trends
Cannabis Use Disorder Treatment Market by Type, Treatment, End User, Region | Forecast 2023 to 2033
Cannabis Use Disorder Treatment Market Snapshot (2023 to 2033)
Valued at US$ 1.57 billion in 2022, the market for cannabis use disorder treatment is foreseen to rise to US$ 1.65 billion in FY 2023, representing a Y-o-Y increase of over 5%. Across the forecast period ranging from 2023 to 2033, the industry is likely to gain traction at a CAGR of 4.9%, reaching a market value of US$ 2.66 billion. The United Nations Office on Drugs and Crime (UNODC) reports that as of 2020, around 275 million people consumed drugs worldwide, while over 36 million people suffered from drug use disorders.
Between 2010 and 2019, the number of people using drugs increased by 22%, owing in part to global population growth. Based on demographic changes alone, current projections suggest an 11% rise in the number of people who use drugs globally by 2030- and a marked increase of 40% in Africa, due to its rapidly growing young population. All these factors and statistics are prompting healthcare providers to invest in top-of-the-line treatments, therapeutics, and diagnostic procedures, paving way for significant market developments.
At present, cannabis use disorder is treated with counseling and therapy, though several medications are being investigated as potential alternatives. Experts opine that should a concrete drug be discovered; it may be combined with therapy to offer the best prognosis for patients. A CUD diagnosis can be complicated by comorbid or co-occurring mental health conditions. For instance, cannabis use disorder is strongly associated with both major depression and generalized anxiety disorder. Some studies have also found higher rates of cannabis use disorder in people with post-traumatic stress disorder.
Prominent treatment providers in the market are leveraging a host of therapeutic and combat approaches. These include an amalgamation of measures, such as conducting pipeline studies to develop effective drug candidates, offering therapy sessions in-house, or collaborating with healthcare tech providers to design apps aimed at helping reduce cannabis and opioid dependence in phased manners.
|
Data Points |
Key Statistics |
|
Documented Market Value for CUD Treatment in 2022 |
US$ 1.57 billion |
|
Expected Market Value for CUD Treatment in 2023 |
US$ 1.65 billion |
|
Anticipated Market Value for CUD Treatment in 2033 |
US$ 2.66 billion |
|
Global Growth Rate (2023 to 2033) |
4.9% CAGR |
Let us know your requirement to get
100% FREE customization
Cannabis Use Disorder Treatment Historical Analysis 2018 to 2022 vs. Future Prospects 2023 to 2033
According to Future Market Insights, cannabis use disorder treatment experienced significant uptake from 2018 to 2022, experiencing a CAGR of 4.6%, given the alarming increase in the number of users dependent on cannabis for recreational use. The bulk of marijuana or cannabis consumption is concentrated within the USA. It was reported that over 50% of adults in the country (over 128 million) have consumed it, despite being contraband under Federal Law. Most treatment approaches have included a host of approaches, from counseling & behavioral therapy to de-addiction drugs.
Moreover, several countries have pushed for legalizing cannabis consumption- a move that is expected to significantly reduce dependence. For instance, in December 2022, the state of Montana lifted the ban on recreational cannabis, bolstering marijuana businesses and generating millions of dollars in new tax revenue for the state and local governments. Consumption of cannabis further rose during the COVID-19 pandemic, as people sought ways to cope with general anxiety and get some stress relief.
In the future, the scope for cannabis use disorder treatment is only expected to rise, with a host of therapeutic and treatment approaches on the cards. A core focus area is expected to be the development of pharmacological treatments. The National Center for Biotechnology Information (NCBI), for instance, has identified eight trials with a total of 667 study participants. They were administered Dronabinol, a drug that significantly reduced cannabis withdrawal symptoms. Other similar drugs are expected to be developed in forthcoming years.
Prominent Drivers Influencing Market Growth of Cannabis Use Disorder Treatment
A Generic Increase in Substance Abuse Globally providing Impetus to Cannabis Use Disorder Treatment
Cannabis, or marijuana, remains the most widely used recreational drug in the world, and its usage stats are staggering. As per the World Health Organization (W.H.O), approximately 147 million people, or 2.5% of the global population consume marijuana. Much like any industry, the cannabis industry offers different products to satisfy the unique needs of the target customers. On the other hand, consumers from different generations have developed specific preferences for product types. 43.6% of consumers prefer flowers, 16.6% vapor pens, 9.8% concentrates, and 20.2% prerolls and edibles respectively.
As per the UNODC’s report, around 284 million people aged 15-64 used drugs worldwide in 2020, a 26% increase over the previous decade. Young people are using more drugs, with use levels today in many countries higher than with the previous generation. Globally, the report estimates that 11.2 million people worldwide were injecting drugs. Around half of this number were living with hepatitis C, 1.4 million were living with HIV, and 1.2 million were living with both.
In Africa and South and Central America, the largest proportion of people in treatment for drug use disorders is there primarily for cannabis use disorders. In the USA and Canada, overdose deaths, predominantly driven by an epidemic of the non-medical use of fentanyl, continue to break records. Preliminary estimates in the USA point to more than 107,000 drug overdose deaths in 2021, up from nearly 92,000 in 2020.
Healthcare Practitioners and Addicts Leveraging Technology to Undertake De-Addiction Programs
Undoubtedly, technology has revolutionized the global healthcare industry, introducing a broad range of treatment options, diagnoses, and therapies for previously incurable diseases and conditions. Substance abuse treatment is no stranger when it comes to utilizing the power of the virtual world. The most popular applications are those aimed at helping users quit smoking since it is the most common way of ingesting weed, marijuana, and other psychotropic substances. As per the Centers for Disease Control and Prevention (CDC), smoking is the leading cause of preventable deaths, and more than 16 million people across the USA live with smoking-related diseases.
A number of smartphone apps have been designed to help ease the burden of substance abuse. Flamy, for instance, provides two options for the smoking cessation journey. One can either choose the one less everyday plan, or the 14 Days Challenge if users are looking to fast-track their results. The app provides a variety of stop-smoking cards and allows users to challenge their friends to quit smoking together.
Another app titled Get Rich or Die Smoking offers a sophisticated reward system that includes a variety of trophies one can obtain. It supports several currencies and offers detailed statistics on the user’s progress. The app also has a community chat to keep users encouraged on their journey, by helping them talk with other people trying to quit. It even offers a relapse button to help get back on track to achieving said goals.
Find your sweet spots for generating winning opportunities in this market.
Talk to AnalystRegion-wise Analysis
How will Cannabis Use Disorder Treatment Assume Shape in North America?
An Alarming Increase in Substance Abuse Cases pushing for Stringent Governmental Regulations
North America is expected to generate ample growth opportunities for cannabis use disorder treatment. As per Future Market Insights, the region is anticipated to account for nearly 45% of all treatments. The CDC projects that marijuana is the most commonly used federally illegal drug in the USA. As of 2019, 48.2 million people, or 18% of the population, have consumed it at least once. It also claims that approximately 3 in 10 people who consume marijuana have marijuana use disorder.
More recently, in January 2023, there were over 7,000 cases of accidental marijuana ingestion by children younger than five years of age between 2017 and 2021. This mostly happened via the consumption of edibles such as brownies and gummies. Also, the National Poison Data System reported that in 2020, pediatric cases of edible marijuana ingestion accounted for more than 40% of all human poison exposures.
Attributed to these alarming statistics, the government has endeavored to reduce incidences of illegal cannabis consumption. For instance, in October 2022, the US Parliament urged federal agencies to re-evaluate the classification of cannabis as a Schedule I controlled substance, in line with heroin and LSD with no accepted medical use. This would permit its use as a Schedule II or III drug under the Controlled Substances Act, for medical use. This would supposedly help prevent abuse. Likewise, President Biden met with Mexican officials to put a plan in action for stopping illicit drugs passing through the country’s southern border. The drug smuggled is fentanyl, highly addictive and 50 times more potent than heroin.
Will Latin America Provide Expansion Opportunities for Cannabis Use Disorder Treatments?
Efforts Underway to Legalize Recreational Consumption Hope to Reduce Dependence
Latin America is expected to present a wide range of expansion opportunities, attributed to a renewed crackdown on illicit drug consumption, especially across countries such as Mexico, Uruguay, and Panama. Over the years, the Americas have initiated reforms of cannabis laws and policies and have opened paths to regulation. In 2013, Uruguay became the first country to pass legislation creating a national legal market for medical and non-medical cannabis.
More than implementing regulations designed to completely cease cannabis consumption, countries across the region are instead seeking to legalize recreational use, in the hopes of expecting overall dependence. Taking Uruguay’s case, the Senate has approved ground-breaking legislation legalizing marijuana, becoming the first nation in the world to oversee the production and sale of the drug. Consequently, a number of manufacturers are finding it easier to enter the market.
For instance, in December 2022, Vertican Growth Inc. entered the cannabis cultivation and manufacturing landscape in Uruguay. The company did so by acquiring 100% stakes in Algamur SA, Wemblar Corporation SA, and Dukiliu Trade SA- three regional companies involved in cannabis cultivation for manufacturing pharmaceutical-grade products. Overall, the Latin American market for cannabis use disorder treatment is likely to flourish at a CAGR of 4.5% until 2033
What are the Growth Prospects for Cannabis Use Disorder Treatment in Europe?
Presence of Effective and Comprehensive Treatment Programs in Key Countries Driving Growth
Europe is anticipated to be an important arena for treating cannabis use disorders during the 2023 to 2033 assessment period, expected to expand at a CAGR of 4%. A variety of evidence-based treatments are available for cannabis use disorders. Compared with standard treatment in place, these interventions are more effective in reducing the frequency and quantity of substance use, as well as the severity of substance use-related problems.
Most countries in Europe offer evidence-based treatment programs for cannabis use disorders. These follow either a general substance use treatment approach or a cannabis-specific approach. Population surveys indicate that cannabis is the most widely used illicit substance in most European countries. Estimates suggest 5 % of adults aged 15-64 years in the European Union, or 18 million adult Europeans, used cannabis in 2014, while 74 million adult Europeans reported having used cannabis at least once in their life.
In October 2022, Germany laid out a bold plan to fully legalize recreational cannabis for people aged 18 and over. For now, Germany and the Commission are in preliminary discussions exchanging arguments. The official notification procedure will start in 2023. Through this approach, the country hopes to reduce overall dependence on cannabis, thus reducing the burden of substance abuse in forthcoming years.
A unified Market Research Subscription Platform, built for today's disparate research needs.
Category-wise Insights
Which Type of Cannabis Use Disorder Treatment is Most Prevalent?
Tobacco/Nicotine and Vaping Addiction to be Most Treated
According to FMI, tobacco/nicotine and vaping addiction are expected to comprise the bulk of all cannabis use disorder treatments, accounting for 67% of all treatments. Nicotine addiction is a complex disorder with no easy cure. Habitual use of tobacco and tobacco products continues to be a significant contributor to health problems worldwide. As per the W.H.O., around 1.3 billion are addicted to tobacco.
Tobacco use accounts for more than 5 million deaths worldwide each year, making de-addiction a top priority. Recently, in January 2023, Achieve Life Sciences announced the completion of treatment in its Phase 3 ORCA-3 clinical trial. ORCA-3 is evaluating the smoking cessation efficacy, safety, and tolerability of 3 mg cytisinicline dosed three times daily for either 6 or 12 weeks compared with placebo.
By Treatment, Which Approach is likely to Work Best for Cannabis Use Disorder?
Addicts Seeking Counselling & Behavioral Therapy as the Most Convenient Option
Based on treatment, cannabis use disorder is expected to be addressed maximum through counseling & behavioral therapy. This segment is expected to expand the fastest, registering a CAGR of 5.5% during the 2023 to 2033 period of assessment. This approach is heavily relied upon because medication-based treatment is still in its nascent stages.
Moreover, counseling & behavioral therapy permit de-addiction in a gradual and phased manner. This prevents the onset of withdrawal symptoms. With the advent of technology, it is now very easy to avail of counseling and therapy sessions in the virtual space. Applications such as Pear reSET, Sober Grid, and Nomo have all gained widespread popularity in the USA.
The Start-up Ecosystem: How Key Players are making Cannabis Use Disorder Treatment Easier
As substance abuse becomes an area of concern, a plethora of start-ups are making their presence known across all continents. These players not only assist patients in giving up recreational cannabis consumption but also help them get de-addicted from tobacco, alcohol, and other psychotropic substances.
- Beyond Lucid Technologies has embarked on a mission to eliminate the scourge of addiction by providing smart connectivity to ambulances and hospitals before a patient’s arrival. The company deploys a unique CPaaS interface, helping share details of critical health information with mobile medical professionals even before they arrive on the scene. With respect to substance addiction, the software traces instances of automobile accidents to identify victims involved in it as a result of consuming a psychotropic substance
- Cloud 9 is a telehealth data and communication solution designed specifically for integrated care collaboration. The startup connects city and county public healthcare to public safety and social services addressing the needs of vulnerable populations. Cloud 9 is also the rest collaborative telehealth product that connects police, fire, and EMS to remote mental health clinicians, allowing them to jointly treat patients experiencing a mental health crisis out in the community.
- Curatio builds private, mobile social health networks to improve adherence and self-management using artificial intelligence and peer support. The SaaS platform is available in 102 countries and 20 languages and is licensed on an annually renewable basis to pharmaceutical and specialty pharmacy companies, payers, providers, research, and government organizations.
- Goldfinch Health provides the Goldfinch Guide, to help patients navigate their surgical journey and reduce opioid use. When an employee needs surgery, the employee is matched with a Goldfinch Guide and a Nurse Navigator. Goldfinch Nurse Navigators work with members to understand the path to surgery, clarify their goals, and tailor plans to support them through a critical time.
Competitive Landscape
While a majority of cannabis use disorder treatments are based on counseling and therapy, healthcare companies are conducting extensive clinical trials, implementing research & development projects, and collaborating with major funding agencies and other established market players. Some key players profiled in this report include Cipla Limited, Intas Pharmaceuticals Limited, Orexo AB, and Allergan plc. to name a few.
- Orexo AB is a prominent face in the cannabis use disorder treatment domain. Its amorphOX® drug delivery technology is highly scalable, possessing unique properties which support highly differentiated pharmaceutical products. One of its pipeline projects includes the OX124 medication for treating opioid overdose. Containing Naloxone as its API, the drug is expected to be launched in the US market by the 2nd half of 2023.
- In November 2022, Indivor Plc. entered into a definitive agreement with Opiant Pharmaceuticals Inc. wherein the former will acquire the latter so as to cement its position as a leader in addiction treatment. Through this acquisition, Indivor will now supervise the potential of OPNT003, an opioid overdose treatment drug that will reduce dependence on illicit drugs such as fentanyl. Fentanyl is responsible for over 100,000 deaths due to overdose across the USA
- BioCorRx Inc. announced a partnership with Government Plus LLC, a leading provider of private sector healthcare to veterans, for expanding its Beat Addiction Recovery Program. BioCorRx Inc. is an addiction treatment solutions company offering a unique approach to the treatment of substance use and other related disorders. Beat Addiction Recovery is a substance use disorder recovery program that typically includes BioCorRx's proprietary Cognitive Behavioral Therapy (CBT) modules along with peer support via mobile app along with medication prescribed by an independent treating physician under their discretion.
Report Scope
|
Report Attribute |
Details |
|
Growth Rate |
CAGR of 4.9% from 2023 to 2033 |
|
Market Value in 2023 |
US$ 1.65 billion |
|
Market Value in 2033 |
US$ 2.66 billion |
|
Base Year for Estimation |
2022 |
|
Historical Data |
2018 to 2022 |
|
Forecast Period |
2023 to 2033 |
|
Quantitative Units |
Revenue in US$ Million and CAGR from 2023 to 2033 |
|
Report Coverage |
Revenue Forecast, Company Ranking, Competitive Landscape, Growth Factors, Trends, and Pricing Analysis |
|
Segments Covered |
|
|
Regions Covered |
|
|
Key Countries Profiled |
|
|
Key Companies Profiled |
|
|
Report Customization & Pricing |
Available upon Request |
Key Segments Profiled in the Cannabis Use Disorder Treatment Industry Analysis
By Type:
- Tobacco/Nicotine and Vaping
- Alcohol
- Marijuana
- Synthetic Cannabinoids
- Others
By Treatment:
- Detoxification
- Counselling & Behavioral Therapy
- Medication
- Support Group
By End User:
- Hospitals and Clinics
- Rehabilitation Centers
- Others
By Region:
- North America
- Latin America
- Europe
- East Asia
- South Asia
- Oceania
- Middle East & Africa
Frequently Asked Questions
As of 2022, the market for cannabis use disorder treatment was valued at US$ 1.57 billion
From 2018 to 2022, the cannabis use disorder treatment market expanded at a CAGR of 4.6%
By the end of 2023, the market worth of cannabis use disorder treatment is expected to reach US$ 1.65 billion
As per Future Market Insights, the cannabis use disorder treatment market is forecast to expand at a CAGR of 4.9% from 2023 to 2033
As of 2033, cannabis use disorder treatment is expected to contribute US$ 2.66 billion in revenue
As of 2023, the North American cannabis use disorder treatment market is expected to generate 45% revenue
Latin America is expected to yield major opportunities, expected to clock a 4.5% CAGR
Treatment for tobacco/nicotine and vaping will be most prominent, comprising 67% of the revenue pie
Counselling & behavioral therapy will account for maximum treatment approaches, expected to surge at a CAGR of 5.5%
Table of Content
1. Executive Summary | Cannabis Use Disorder Treatment Market
1.1. Global Market Outlook
1.2. Demand-side Trends
1.3. Supply-side Trends
1.4. Technology Roadmap Analysis
1.5. Analysis and Recommendations
2. Market Overview
2.1. Market Coverage / Taxonomy
2.2. Market Definition / Scope / Limitations
3. Market Background
3.1. Market Dynamics
3.1.1. Drivers
3.1.2. Restraints
3.1.3. Opportunity
3.1.4. Trends
3.2. Scenario Forecast
3.2.1. Demand in Optimistic Scenario
3.2.2. Demand in Likely Scenario
3.2.3. Demand in Conservative Scenario
3.3. Opportunity Map Analysis
3.4. Investment Feasibility Matrix
3.5. PESTLE and Porter’s Analysis
3.6. Regulatory Landscape
3.6.1. By Key Regions
3.6.2. By Key Countries
3.7. Regional Parent Market Outlook
4. Global Market Analysis 2018 to 2022 and Forecast, 2023 to 2033
4.1. Historical Market Size Value (US$ Million) Analysis, 2018 to 2022
4.2. Current and Future Market Size Value (US$ Million) Projections, 2023 to 2033
4.2.1. Y-o-Y Growth Trend Analysis
4.2.2. Absolute $ Opportunity Analysis
5. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Type
5.1. Introduction / Key Findings
5.2. Historical Market Size Value (US$ Million) Analysis By Type, 2018 to 2022
5.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Type, 2023 to 2033
5.3.1. Tobacco/Nicotine and Vaping
5.3.2. Alcohol
5.3.3. Marijuana
5.3.4. Synthetic Cannabinoids
5.3.5. Others
5.4. Y-o-Y Growth Trend Analysis By Type, 2018 to 2022
5.5. Absolute $ Opportunity Analysis By Type, 2023 to 2033
6. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Treatment
6.1. Introduction / Key Findings
6.2. Historical Market Size Value (US$ Million) Analysis By Treatment, 2018 to 2022
6.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Treatment, 2023 to 2033
6.3.1. Detoxification
6.3.2. Counselling & Behavioral Therapy
6.3.3. Medication
6.3.4. Support Group
6.4. Y-o-Y Growth Trend Analysis By Treatment, 2018 to 2022
6.5. Absolute $ Opportunity Analysis By Treatment, 2023 to 2033
7. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By End User
7.1. Introduction / Key Findings
7.2. Historical Market Size Value (US$ Million) Analysis By End-User, 2018 to 2022
7.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By End-User, 2023 to 2033
7.3.1. Hospitals and Clinics
7.3.2. Rehabilitation Centers
7.3.3. Others
7.4. Y-o-Y Growth Trend Analysis By End-User, 2018 to 2022
7.5. Absolute $ Opportunity Analysis By End-User, 2023 to 2033
8. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Region
8.1. Introduction
8.2. Historical Market Size Value (US$ Million) Analysis By Region, 2018 to 2022
8.3. Current Market Size Value (US$ Million) Analysis and Forecast By Region, 2023 to 2033
8.3.1. North America
8.3.2. Latin America
8.3.3. Europe
8.3.4. South Asia
8.3.5. East Asia
8.3.6. Oceania
8.3.7. Middle East & Africa
8.4. Market Attractiveness Analysis By Region
9. North America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
9.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
9.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
9.2.1. By Country
9.2.1.1. United States
9.2.1.2. Canada
9.2.2. By Type
9.2.3. By Treatment
9.2.4. By End-User
9.3. Market Attractiveness Analysis
9.3.1. By Country
9.3.2. By Type
9.3.3. By Treatment
9.3.4. By End-User
9.4. Key Takeaways
10. Latin America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
10.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
10.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
10.2.1. By Country
10.2.1.1. Brazil
10.2.1.2. Mexico
10.2.1.3. Rest of Latin America
10.2.2. By Type
10.2.3. By Treatment
10.2.4. By End-User
10.3. Market Attractiveness Analysis
10.3.1. By Country
10.3.2. By Type
10.3.3. By Treatment
10.3.4. By End-User
10.4. Key Takeaways
11. Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
11.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
11.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
11.2.1. By Country
11.2.1.1. Germany
11.2.1.2. United Kingdom
11.2.1.3. France
11.2.1.4. Spain
11.2.1.5. Italy
11.2.1.6. Rest of Europe
11.2.2. By Type
11.2.3. By Treatment
11.2.4. By End-User
11.3. Market Attractiveness Analysis
11.3.1. By Country
11.3.2. By Type
11.3.3. By Treatment
11.3.4. By End-User
11.4. Key Takeaways
12. South Asia Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
12.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
12.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
12.2.1. By Country
12.2.1.1. India
12.2.1.2. Malaysia
12.2.1.3. Singapore
12.2.1.4. Thailand
12.2.1.5. Rest of South Asia
12.2.2. By Type
12.2.3. By Treatment
12.2.4. By End-User
12.3. Market Attractiveness Analysis
12.3.1. By Country
12.3.2. By Type
12.3.3. By Treatment
12.3.4. By End-User
12.4. Key Takeaways
13. East Asia Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
13.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
13.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
13.2.1. By Country
13.2.1.1. China
13.2.1.2. Japan
13.2.1.3. South Korea
13.2.2. By Type
13.2.3. By Treatment
13.2.4. By End-User
13.3. Market Attractiveness Analysis
13.3.1. By Country
13.3.2. By Type
13.3.3. By Treatment
13.3.4. By End-User
13.4. Key Takeaways
14. Oceania Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
14.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
14.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
14.2.1. By Country
14.2.1.1. Australia
14.2.1.2. New Zealand
14.2.2. By Type
14.2.3. By Treatment
14.2.4. By End-User
14.3. Market Attractiveness Analysis
14.3.1. By Country
14.3.2. By Type
14.3.3. By Treatment
14.3.4. By End-User
14.4. Key Takeaways
15. MEA Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
15.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
15.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
15.2.1. By Country
15.2.1.1. GCC Countries
15.2.1.2. South Africa
15.2.1.3. Israel
15.2.1.4. Rest of Middle East and Africa (MEA)
15.2.2. By Type
15.2.3. By Treatment
15.2.4. By End-User
15.3. Market Attractiveness Analysis
15.3.1. By Country
15.3.2. By Type
15.3.3. By Treatment
15.3.4. By End-User
15.4. Key Takeaways
16. Key Countries Market Analysis
16.1. UNITED STATES
16.1.1. Pricing Analysis
16.1.2. Market Share Analysis, 2022
16.1.2.1. By Type
16.1.2.2. By Treatment
16.1.2.3. By End-User
16.2. Canada
16.2.1. Pricing Analysis
16.2.2. Market Share Analysis, 2022
16.2.2.1. By Type
16.2.2.2. By Treatment
16.2.2.3. By End-User
16.3. Brazil
16.3.1. Pricing Analysis
16.3.2. Market Share Analysis, 2022
16.3.2.1. By Type
16.3.2.2. By Treatment
16.3.2.3. By End-User
16.4. Mexico
16.4.1. Pricing Analysis
16.4.2. Market Share Analysis, 2022
16.4.2.1. By Type
16.4.2.2. By Treatment
16.4.2.3. By End-User
16.5. Germany
16.5.1. Pricing Analysis
16.5.2. Market Share Analysis, 2022
16.5.2.1. By Type
16.5.2.2. By Treatment
16.5.2.3. By End-User
16.6. UNITED KINGDOM
16.6.1. Pricing Analysis
16.6.2. Market Share Analysis, 2022
16.6.2.1. By Type
16.6.2.2. By Treatment
16.6.2.3. By End-User
16.7. France
16.7.1. Pricing Analysis
16.7.2. Market Share Analysis, 2022
16.7.2.1. By Type
16.7.2.2. By Treatment
16.7.2.3. By End-User
16.8. Spain
16.8.1. Pricing Analysis
16.8.2. Market Share Analysis, 2022
16.8.2.1. By Type
16.8.2.2. By Treatment
16.8.2.3. By End-User
16.9. Italy
16.9.1. Pricing Analysis
16.9.2. Market Share Analysis, 2022
16.9.2.1. By Type
16.9.2.2. By Treatment
16.9.2.3. By End-User
16.10. India
16.10.1. Pricing Analysis
16.10.2. Market Share Analysis, 2022
16.10.2.1. By Type
16.10.2.2. By Treatment
16.10.2.3. By End-User
16.11. Malaysia
16.11.1. Pricing Analysis
16.11.2. Market Share Analysis, 2022
16.11.2.1. By Type
16.11.2.2. By Treatment
16.11.2.3. By End-User
16.12. Singapore
16.12.1. Pricing Analysis
16.12.2. Market Share Analysis, 2022
16.12.2.1. By Type
16.12.2.2. By Treatment
16.12.2.3. By End-User
16.13. Thailand
16.13.1. Pricing Analysis
16.13.2. Market Share Analysis, 2022
16.13.2.1. By Type
16.13.2.2. By Treatment
16.13.2.3. By End-User
16.14. China
16.14.1. Pricing Analysis
16.14.2. Market Share Analysis, 2022
16.14.2.1. By Type
16.14.2.2. By Treatment
16.14.2.3. By End-User
16.15. Japan
16.15.1. Pricing Analysis
16.15.2. Market Share Analysis, 2022
16.15.2.1. By Type
16.15.2.2. By Treatment
16.15.2.3. By End-User
16.16. South Korea
16.16.1. Pricing Analysis
16.16.2. Market Share Analysis, 2022
16.16.2.1. By Type
16.16.2.2. By Treatment
16.16.2.3. By End-User
16.17. Australia
16.17.1. Pricing Analysis
16.17.2. Market Share Analysis, 2022
16.17.2.1. By Type
16.17.2.2. By Treatment
16.17.2.3. By End-User
16.18. New Zealand
16.18.1. Pricing Analysis
16.18.2. Market Share Analysis, 2022
16.18.2.1. By Type
16.18.2.2. By Treatment
16.18.2.3. By End-User
16.19. GCC Countries
16.19.1. Pricing Analysis
16.19.2. Market Share Analysis, 2022
16.19.2.1. By Type
16.19.2.2. By Treatment
16.19.2.3. By End-User
16.20. South Africa
16.20.1. Pricing Analysis
16.20.2. Market Share Analysis, 2022
16.20.2.1. By Type
16.20.2.2. By Treatment
16.20.2.3. By End-User
16.21. Israel
16.21.1. Pricing Analysis
16.21.2. Market Share Analysis, 2022
16.21.2.1. By Type
16.21.2.2. By Treatment
16.21.2.3. By End-User
17. Market Structure Analysis
17.1. Competition Dashboard
17.2. Competition Benchmarking
17.3. Market Share Analysis of Top Players
17.3.1. By Regional
17.3.2. By Type
17.3.3. By Treatment
17.3.4. By End-User
18. Competition Analysis
18.1. Competition Deep Dive
18.1.1. Cipla Limited
18.1.1.1. Overview
18.1.1.2. Product Portfolio
18.1.1.3. Profitability by Market Segments
18.1.1.4. Sales Footprint
18.1.1.5. Strategy Overview
18.1.1.5.1. Marketing Strategy
18.1.2. Intas Pharmaceuticals Limited
18.1.2.1. Overview
18.1.2.2. Product Portfolio
18.1.2.3. Profitability by Market Segments
18.1.2.4. Sales Footprint
18.1.2.5. Strategy Overview
18.1.2.5.1. Marketing Strategy
18.1.3. Orexo AB
18.1.3.1. Overview
18.1.3.2. Product Portfolio
18.1.3.3. Profitability by Market Segments
18.1.3.4. Sales Footprint
18.1.3.5. Strategy Overview
18.1.3.5.1. Marketing Strategy
18.1.4. Allergan plc
18.1.4.1. Overview
18.1.4.2. Product Portfolio
18.1.4.3. Profitability by Market Segments
18.1.4.4. Sales Footprint
18.1.4.5. Strategy Overview
18.1.4.5.1. Marketing Strategy
18.1.5. Alkermes plc.
18.1.5.1. Overview
18.1.5.2. Product Portfolio
18.1.5.3. Profitability by Market Segments
18.1.5.4. Sales Footprint
18.1.5.5. Strategy Overview
18.1.5.5.1. Marketing Strategy
18.1.6. Indivior plc
18.1.6.1. Overview
18.1.6.2. Product Portfolio
18.1.6.3. Profitability by Market Segments
18.1.6.4. Sales Footprint
18.1.6.5. Strategy Overview
18.1.6.5.1. Marketing Strategy
18.1.7. Noramco
18.1.7.1. Overview
18.1.7.2. Product Portfolio
18.1.7.3. Profitability by Market Segments
18.1.7.4. Sales Footprint
18.1.7.5. Strategy Overview
18.1.7.5.1. Marketing Strategy
18.1.8. Mallinckrodt plc
18.1.8.1. Overview
18.1.8.2. Product Portfolio
18.1.8.3. Profitability by Market Segments
18.1.8.4. Sales Footprint
18.1.8.5. Strategy Overview
18.1.8.5.1. Marketing Strategy
18.1.9. BioCorRx Inc.
18.1.9.1. Overview
18.1.9.2. Product Portfolio
18.1.9.3. Profitability by Market Segments
18.1.9.4. Sales Footprint
18.1.9.5. Strategy Overview
18.1.9.5.1. Marketing Strategy
18.1.10. Glenmark Pharmaceuticals Ltd.
18.1.10.1. Overview
18.1.10.2. Product Portfolio
18.1.10.3. Profitability by Market Segments
18.1.10.4. Sales Footprint
18.1.10.5. Strategy Overview
18.1.10.5.1. Marketing Strategy
18.1.11. Dr. Reddy’s Laboratories
18.1.11.1. Overview
18.1.11.2. Product Portfolio
18.1.11.3. Profitability by Market Segments
18.1.11.4. Sales Footprint
18.1.11.5. Strategy Overview
18.1.11.5.1. Marketing Strategy
18.1.12. Purdue Pharma L.P.
18.1.12.1. Overview
18.1.12.2. Product Portfolio
18.1.12.3. Profitability by Market Segments
18.1.12.4. Sales Footprint
18.1.12.5. Strategy Overview
18.1.12.5.1. Marketing Strategy
19. Assumptions & Acronyms Used
20. Research Methodology
Let us know your requirement to get
100% FREE customization
List of Tables
Table 1: Global Market Value (US$ Million) Forecast by Region, 2018 to 2033
Table 2: Global Market Value (US$ Million) Forecast by Type, 2018 to 2033
Table 3: Global Market Value (US$ Million) Forecast by Treatment, 2018 to 2033
Table 4: Global Market Value (US$ Million) Forecast by End-User, 2018 to 2033
Table 5: North America Market Value (US$ Million) Forecast by Country, 2018 to 2033
Table 6: North America Market Value (US$ Million) Forecast by Type, 2018 to 2033
Table 7: North America Market Value (US$ Million) Forecast by Treatment, 2018 to 2033
Table 8: North America Market Value (US$ Million) Forecast by End-User, 2018 to 2033
Table 9: Latin America Market Value (US$ Million) Forecast by Country, 2018 to 2033
Table 10: Latin America Market Value (US$ Million) Forecast by Type, 2018 to 2033
Table 11: Latin America Market Value (US$ Million) Forecast by Treatment, 2018 to 2033
Table 12: Latin America Market Value (US$ Million) Forecast by End-User, 2018 to 2033
Table 13: Europe Market Value (US$ Million) Forecast by Country, 2018 to 2033
Table 14: Europe Market Value (US$ Million) Forecast by Type, 2018 to 2033
Table 15: Europe Market Value (US$ Million) Forecast by Treatment, 2018 to 2033
Table 16: Europe Market Value (US$ Million) Forecast by End-User, 2018 to 2033
Table 17: South Asia Market Value (US$ Million) Forecast by Country, 2018 to 2033
Table 18: South Asia Market Value (US$ Million) Forecast by Type, 2018 to 2033
Table 19: South Asia Market Value (US$ Million) Forecast by Treatment, 2018 to 2033
Table 20: South Asia Market Value (US$ Million) Forecast by End-User, 2018 to 2033
Table 21: East Asia Market Value (US$ Million) Forecast by Country, 2018 to 2033
Table 22: East Asia Market Value (US$ Million) Forecast by Type, 2018 to 2033
Table 23: East Asia Market Value (US$ Million) Forecast by Treatment, 2018 to 2033
Table 24: East Asia Market Value (US$ Million) Forecast by End-User, 2018 to 2033
Table 25: Oceania Market Value (US$ Million) Forecast by Country, 2018 to 2033
Table 26: Oceania Market Value (US$ Million) Forecast by Type, 2018 to 2033
Table 27: Oceania Market Value (US$ Million) Forecast by Treatment, 2018 to 2033
Table 28: Oceania Market Value (US$ Million) Forecast by End-User, 2018 to 2033
Table 29: MEA Market Value (US$ Million) Forecast by Country, 2018 to 2033
Table 30: MEA Market Value (US$ Million) Forecast by Type, 2018 to 2033
Table 31: MEA Market Value (US$ Million) Forecast by Treatment, 2018 to 2033
Table 32: MEA Market Value (US$ Million) Forecast by End-User, 2018 to 2033
Find your sweet spots for generating winning opportunities in this market.
Talk to AnalystList of Charts
Figure 1: Global Market Value (US$ Million) by Type, 2023 to 2033
Figure 2: Global Market Value (US$ Million) by Treatment, 2023 to 2033
Figure 3: Global Market Value (US$ Million) by End-User, 2023 to 2033
Figure 4: Global Market Value (US$ Million) by Region, 2023 to 2033
Figure 5: Global Market Value (US$ Million) Analysis by Region, 2018 to 2033
Figure 6: Global Market Value Share (%) and BPS Analysis by Region, 2023 to 2033
Figure 7: Global Market Y-o-Y Growth (%) Projections by Region, 2023 to 2033
Figure 8: Global Market Value (US$ Million) Analysis by Type, 2018 to 2033
Figure 9: Global Market Value Share (%) and BPS Analysis by Type, 2023 to 2033
Figure 10: Global Market Y-o-Y Growth (%) Projections by Type, 2023 to 2033
Figure 11: Global Market Value (US$ Million) Analysis by Treatment, 2018 to 2033
Figure 12: Global Market Value Share (%) and BPS Analysis by Treatment, 2023 to 2033
Figure 13: Global Market Y-o-Y Growth (%) Projections by Treatment, 2023 to 2033
Figure 14: Global Market Value (US$ Million) Analysis by End-User, 2018 to 2033
Figure 15: Global Market Value Share (%) and BPS Analysis by End-User, 2023 to 2033
Figure 16: Global Market Y-o-Y Growth (%) Projections by End-User, 2023 to 2033
Figure 17: Global Market Attractiveness by Type, 2023 to 2033
Figure 18: Global Market Attractiveness by Treatment, 2023 to 2033
Figure 19: Global Market Attractiveness by End-User, 2023 to 2033
Figure 20: Global Market Attractiveness by Region, 2023 to 2033
Figure 21: North America Market Value (US$ Million) by Type, 2023 to 2033
Figure 22: North America Market Value (US$ Million) by Treatment, 2023 to 2033
Figure 23: North America Market Value (US$ Million) by End-User, 2023 to 2033
Figure 24: North America Market Value (US$ Million) by Country, 2023 to 2033
Figure 25: North America Market Value (US$ Million) Analysis by Country, 2018 to 2033
Figure 26: North America Market Value Share (%) and BPS Analysis by Country, 2023 to 2033
Figure 27: North America Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033
Figure 28: North America Market Value (US$ Million) Analysis by Type, 2018 to 2033
Figure 29: North America Market Value Share (%) and BPS Analysis by Type, 2023 to 2033
Figure 30: North America Market Y-o-Y Growth (%) Projections by Type, 2023 to 2033
Figure 31: North America Market Value (US$ Million) Analysis by Treatment, 2018 to 2033
Figure 32: North America Market Value Share (%) and BPS Analysis by Treatment, 2023 to 2033
Figure 33: North America Market Y-o-Y Growth (%) Projections by Treatment, 2023 to 2033
Figure 34: North America Market Value (US$ Million) Analysis by End-User, 2018 to 2033
Figure 35: North America Market Value Share (%) and BPS Analysis by End-User, 2023 to 2033
Figure 36: North America Market Y-o-Y Growth (%) Projections by End-User, 2023 to 2033
Figure 37: North America Market Attractiveness by Type, 2023 to 2033
Figure 38: North America Market Attractiveness by Treatment, 2023 to 2033
Figure 39: North America Market Attractiveness by End-User, 2023 to 2033
Figure 40: North America Market Attractiveness by Country, 2023 to 2033
Figure 41: Latin America Market Value (US$ Million) by Type, 2023 to 2033
Figure 42: Latin America Market Value (US$ Million) by Treatment, 2023 to 2033
Figure 43: Latin America Market Value (US$ Million) by End-User, 2023 to 2033
Figure 44: Latin America Market Value (US$ Million) by Country, 2023 to 2033
Figure 45: Latin America Market Value (US$ Million) Analysis by Country, 2018 to 2033
Figure 46: Latin America Market Value Share (%) and BPS Analysis by Country, 2023 to 2033
Figure 47: Latin America Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033
Figure 48: Latin America Market Value (US$ Million) Analysis by Type, 2018 to 2033
Figure 49: Latin America Market Value Share (%) and BPS Analysis by Type, 2023 to 2033
Figure 50: Latin America Market Y-o-Y Growth (%) Projections by Type, 2023 to 2033
Figure 51: Latin America Market Value (US$ Million) Analysis by Treatment, 2018 to 2033
Figure 52: Latin America Market Value Share (%) and BPS Analysis by Treatment, 2023 to 2033
Figure 53: Latin America Market Y-o-Y Growth (%) Projections by Treatment, 2023 to 2033
Figure 54: Latin America Market Value (US$ Million) Analysis by End-User, 2018 to 2033
Figure 55: Latin America Market Value Share (%) and BPS Analysis by End-User, 2023 to 2033
Figure 56: Latin America Market Y-o-Y Growth (%) Projections by End-User, 2023 to 2033
Figure 57: Latin America Market Attractiveness by Type, 2023 to 2033
Figure 58: Latin America Market Attractiveness by Treatment, 2023 to 2033
Figure 59: Latin America Market Attractiveness by End-User, 2023 to 2033
Figure 60: Latin America Market Attractiveness by Country, 2023 to 2033
Figure 61: Europe Market Value (US$ Million) by Type, 2023 to 2033
Figure 62: Europe Market Value (US$ Million) by Treatment, 2023 to 2033
Figure 63: Europe Market Value (US$ Million) by End-User, 2023 to 2033
Figure 64: Europe Market Value (US$ Million) by Country, 2023 to 2033
Figure 65: Europe Market Value (US$ Million) Analysis by Country, 2018 to 2033
Figure 66: Europe Market Value Share (%) and BPS Analysis by Country, 2023 to 2033
Figure 67: Europe Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033
Figure 68: Europe Market Value (US$ Million) Analysis by Type, 2018 to 2033
Figure 69: Europe Market Value Share (%) and BPS Analysis by Type, 2023 to 2033
Figure 70: Europe Market Y-o-Y Growth (%) Projections by Type, 2023 to 2033
Figure 71: Europe Market Value (US$ Million) Analysis by Treatment, 2018 to 2033
Figure 72: Europe Market Value Share (%) and BPS Analysis by Treatment, 2023 to 2033
Figure 73: Europe Market Y-o-Y Growth (%) Projections by Treatment, 2023 to 2033
Figure 74: Europe Market Value (US$ Million) Analysis by End-User, 2018 to 2033
Figure 75: Europe Market Value Share (%) and BPS Analysis by End-User, 2023 to 2033
Figure 76: Europe Market Y-o-Y Growth (%) Projections by End-User, 2023 to 2033
Figure 77: Europe Market Attractiveness by Type, 2023 to 2033
Figure 78: Europe Market Attractiveness by Treatment, 2023 to 2033
Figure 79: Europe Market Attractiveness by End-User, 2023 to 2033
Figure 80: Europe Market Attractiveness by Country, 2023 to 2033
Figure 81: South Asia Market Value (US$ Million) by Type, 2023 to 2033
Figure 82: South Asia Market Value (US$ Million) by Treatment, 2023 to 2033
Figure 83: South Asia Market Value (US$ Million) by End-User, 2023 to 2033
Figure 84: South Asia Market Value (US$ Million) by Country, 2023 to 2033
Figure 85: South Asia Market Value (US$ Million) Analysis by Country, 2018 to 2033
Figure 86: South Asia Market Value Share (%) and BPS Analysis by Country, 2023 to 2033
Figure 87: South Asia Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033
Figure 88: South Asia Market Value (US$ Million) Analysis by Type, 2018 to 2033
Figure 89: South Asia Market Value Share (%) and BPS Analysis by Type, 2023 to 2033
Figure 90: South Asia Market Y-o-Y Growth (%) Projections by Type, 2023 to 2033
Figure 91: South Asia Market Value (US$ Million) Analysis by Treatment, 2018 to 2033
Figure 92: South Asia Market Value Share (%) and BPS Analysis by Treatment, 2023 to 2033
Figure 93: South Asia Market Y-o-Y Growth (%) Projections by Treatment, 2023 to 2033
Figure 94: South Asia Market Value (US$ Million) Analysis by End-User, 2018 to 2033
Figure 95: South Asia Market Value Share (%) and BPS Analysis by End-User, 2023 to 2033
Figure 96: South Asia Market Y-o-Y Growth (%) Projections by End-User, 2023 to 2033
Figure 97: South Asia Market Attractiveness by Type, 2023 to 2033
Figure 98: South Asia Market Attractiveness by Treatment, 2023 to 2033
Figure 99: South Asia Market Attractiveness by End-User, 2023 to 2033
Figure 100: South Asia Market Attractiveness by Country, 2023 to 2033
Figure 101: East Asia Market Value (US$ Million) by Type, 2023 to 2033
Figure 102: East Asia Market Value (US$ Million) by Treatment, 2023 to 2033
Figure 103: East Asia Market Value (US$ Million) by End-User, 2023 to 2033
Figure 104: East Asia Market Value (US$ Million) by Country, 2023 to 2033
Figure 105: East Asia Market Value (US$ Million) Analysis by Country, 2018 to 2033
Figure 106: East Asia Market Value Share (%) and BPS Analysis by Country, 2023 to 2033
Figure 107: East Asia Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033
Figure 108: East Asia Market Value (US$ Million) Analysis by Type, 2018 to 2033
Figure 109: East Asia Market Value Share (%) and BPS Analysis by Type, 2023 to 2033
Figure 110: East Asia Market Y-o-Y Growth (%) Projections by Type, 2023 to 2033
Figure 111: East Asia Market Value (US$ Million) Analysis by Treatment, 2018 to 2033
Figure 112: East Asia Market Value Share (%) and BPS Analysis by Treatment, 2023 to 2033
Figure 113: East Asia Market Y-o-Y Growth (%) Projections by Treatment, 2023 to 2033
Figure 114: East Asia Market Value (US$ Million) Analysis by End-User, 2018 to 2033
Figure 115: East Asia Market Value Share (%) and BPS Analysis by End-User, 2023 to 2033
Figure 116: East Asia Market Y-o-Y Growth (%) Projections by End-User, 2023 to 2033
Figure 117: East Asia Market Attractiveness by Type, 2023 to 2033
Figure 118: East Asia Market Attractiveness by Treatment, 2023 to 2033
Figure 119: East Asia Market Attractiveness by End-User, 2023 to 2033
Figure 120: East Asia Market Attractiveness by Country, 2023 to 2033
Figure 121: Oceania Market Value (US$ Million) by Type, 2023 to 2033
Figure 122: Oceania Market Value (US$ Million) by Treatment, 2023 to 2033
Figure 123: Oceania Market Value (US$ Million) by End-User, 2023 to 2033
Figure 124: Oceania Market Value (US$ Million) by Country, 2023 to 2033
Figure 125: Oceania Market Value (US$ Million) Analysis by Country, 2018 to 2033
Figure 126: Oceania Market Value Share (%) and BPS Analysis by Country, 2023 to 2033
Figure 127: Oceania Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033
Figure 128: Oceania Market Value (US$ Million) Analysis by Type, 2018 to 2033
Figure 129: Oceania Market Value Share (%) and BPS Analysis by Type, 2023 to 2033
Figure 130: Oceania Market Y-o-Y Growth (%) Projections by Type, 2023 to 2033
Figure 131: Oceania Market Value (US$ Million) Analysis by Treatment, 2018 to 2033
Figure 132: Oceania Market Value Share (%) and BPS Analysis by Treatment, 2023 to 2033
Figure 133: Oceania Market Y-o-Y Growth (%) Projections by Treatment, 2023 to 2033
Figure 134: Oceania Market Value (US$ Million) Analysis by End-User, 2018 to 2033
Figure 135: Oceania Market Value Share (%) and BPS Analysis by End-User, 2023 to 2033
Figure 136: Oceania Market Y-o-Y Growth (%) Projections by End-User, 2023 to 2033
Figure 137: Oceania Market Attractiveness by Type, 2023 to 2033
Figure 138: Oceania Market Attractiveness by Treatment, 2023 to 2033
Figure 139: Oceania Market Attractiveness by End-User, 2023 to 2033
Figure 140: Oceania Market Attractiveness by Country, 2023 to 2033
Figure 141: MEA Market Value (US$ Million) by Type, 2023 to 2033
Figure 142: MEA Market Value (US$ Million) by Treatment, 2023 to 2033
Figure 143: MEA Market Value (US$ Million) by End-User, 2023 to 2033
Figure 144: MEA Market Value (US$ Million) by Country, 2023 to 2033
Figure 145: MEA Market Value (US$ Million) Analysis by Country, 2018 to 2033
Figure 146: MEA Market Value Share (%) and BPS Analysis by Country, 2023 to 2033
Figure 147: MEA Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033
Figure 148: MEA Market Value (US$ Million) Analysis by Type, 2018 to 2033
Figure 149: MEA Market Value Share (%) and BPS Analysis by Type, 2023 to 2033
Figure 150: MEA Market Y-o-Y Growth (%) Projections by Type, 2023 to 2033
Figure 151: MEA Market Value (US$ Million) Analysis by Treatment, 2018 to 2033
Figure 152: MEA Market Value Share (%) and BPS Analysis by Treatment, 2023 to 2033
Figure 153: MEA Market Y-o-Y Growth (%) Projections by Treatment, 2023 to 2033
Figure 154: MEA Market Value (US$ Million) Analysis by End-User, 2018 to 2033
Figure 155: MEA Market Value Share (%) and BPS Analysis by End-User, 2023 to 2033
Figure 156: MEA Market Y-o-Y Growth (%) Projections by End-User, 2023 to 2033
Figure 157: MEA Market Attractiveness by Type, 2023 to 2033
Figure 158: MEA Market Attractiveness by Treatment, 2023 to 2033
Figure 159: MEA Market Attractiveness by End-User, 2023 to 2033
Figure 160: MEA Market Attractiveness by Country, 2023 to 2033
Need specific information?
Request CustomizationExplore Healthcare Insights
View Reports
